A SAGE Publication Editorial Ten years ago, I wrote about my opinion on the status of vascular device technology. 1 At the turn of the century, the decline in the rate of development of these devices was already evident. This decline was related in part to decreasing investment in research and development and also to shifting interest in the device industry away from long-term goals. Corporate interests started to focus on small companies with marginal improvement projects, many of them from outside of the United States. A new generation of small entrepreneurs, many former employees of the corporate device companies, appeared along with venture capitalists willing to risk investing in only small projects with short-term return expectations. Blue-sky disruptive ideas did not fit this financial scheme, but the "keep it simple" paradigm did. Certainly, novel implantable Class III devices have always been complex projects with lengthy Food and Drug Administration (FDA) approval times ranging from 5 to 10 years. The time factor alone conflicts with the objective of a quick return of investment, hence the predominance of marginal improvements seen in the vascular stent arena in the past 20 years. Today, large companies play it safe, focused on maintaining their share of the vascular device market. Things have not changed much lately, and stagnation has set in.
Drug-Eluting Stent
One such shift of direction was the drug-eluting stent (DES). In my opinion, it came about too early. The materials used in the bare metal stent (BMS) had not been perfected, and the metal-vessel wall interaction remained (and still is) incompletely understood. A systematic research of all established metals and alloys and the myriad of new coating materials proposed, including polymers, ceramics, oxides, and organic materials, had not been properly vetted because of the lack of consensus on ways to interpret the experimental evidence. 3 Device surface microengineering was not given much attention, [4] [5] [6] shadowed by the powerful anti-inflammatory drug delivery technology. 7 In my mind, the coating of the stent metal frame with permanent polymers was a way to sweep "under the rug" our concerns about materials that were less than biocompatible. Compared with BMS, the 6-year rates of death and myocardial infarction are the same with DES, but repeat revascularization is definitely lower. 8 This fact made the DES a smashing success and largely helped establish coronary stenting as a reliable therapy. However, had we not been introduced to the DES, continued search for more biocompatible biomaterials, material/tissue interactions, and surface engineering may have taken us to new frontiers.
Later on, the bioresorbable drug-eluting stent (BRS) came along. An old principle with rather discouraging early findings in research animals 9,10 and in patients, 11 when combined with antiproliferative drugs, the BRS acquired a new lease on life. 12 After approval in Europe and the US, late evidence tempered the early optimism. 13, 14 This project, like others before, was started in a way that can be explained as follows.
Heuristic Reasoning
Heuristic refers to a practical reasoning method not guaranteed to be optimal or perfect but sufficient to meet immediate goals. 15 Many times it is used in the decision-making process to choose a path without going through compulsory steps. In our discipline, this approach may have justified investing significant research and development efforts in the coronary BRS based on the assumption that following bioabsorption of the frame, the artery will reorganize itself into a functional unit. I was surprised at how compelling this paradigm was to the interventional cardiology community despite incomplete evidence. Throughout the field of prosthetic implantable devices, prostheses are intended to replace a structure that has lost its integrity. This is true of dental, orthopedic, and ophthalmic implants. A coronary artery with extensive loss of the muscular and elastic structures has lost its backbone. A metal stent provides the functional support for the remainder of its life just as a hip prosthesis replaces a degenerated hip joint or an intraocular lens restores vision. To assume that the damaged vessel will reorganize itself into a functional structure is naively optimistic, at least in advanced lesions. This is in addition to significant compromises imposed by this technology regarding the increased bulk and reduced radial strength of the BRS, requiring additional work at the target site compared with a state-of-the-art metal frame stent.
Old Materials Into New Devices
Without taking a bit of credit from the pioneers of the percutaneous transcatheter aortic valve, combining a traditional biological valve with a vascular stent, either balloon-expandable or self-expanding, was a way to combine preexisting technologies into a new device. The benefit to patients who could not withstand a surgical replacement has been proven, but the associated procedural complications, although diminished from the early experiences, are still present. 16 The devices are still put together with mechanical fastening methods such as stitches and swaging tubes through largely manual, labor-intensive manufacturing. The constituent materials are many decades old and directly derived from the progenitor devices: lyophilized bovine aortic valve or horse pericardium, polymeric fabrics, surgical suture, and medical-grade tubing. Given the success and acceptance of these devices, a deliberate effort should have been made to advance the technology past the early stages. In my opinion, these devices have undergone only incremental improvements and not a breakthrough evolution.
Another example of stagnant development is the aortic stent-graft. Just like the transcatheter aortic valve, these devices combine traditional technologies and materials, such as nitinol alloy and variants of old vascular polymers (eg, polystyrene-terephthalate and polytetrafluoroethylene). This technology seems to work but shares with other large implantable devices a deficient biocompatibility, in other words, poor tissue incorporation and thrombogenicity. 17, 18 A long time after placement, tissue embedment and endothelialization remain incomplete and sometimes sparse, leading to thrombus formation, leaks, and occasional dislodgment. These problems were identified years ago 19 and still persist despite the efforts of the manufacturers to amend these limitations, 20 even though these devices today are more user-friendly and therefore safer than the early-generation models.
At the root of these limitations are the vascular materials. After years of studying with analytical equipment contemporary bioprosthetic device materials, our most significant finding was that these materials elicited similar responses despite being widely different, whether they are alloys, polymers, ceramics, and so on. The reason was related to ambient and manufacturing contamination. 21 The surface contaminants, like airborne molecules and residuals from manufacturing steps, make all surfaces similar to each other, hence the common traits when interacting with blood and tissues. The physicochemical properties of the material, such as hydropathy, surface energy, and chemical reactivity, get blunted by the adsorption of small molecules, averaging out the unique properties of each material. Also, each manufacturing step along the way, including sterilization and packaging, leaves a chemical footprint adding to the blunting effect. 22 When exposing a material to circulating blood, the earliest interaction is with water, electrolytes, and circulating proteins. A fight for surface occupancy is a balance between protein concentration, protein surface affinity, and residence time. All this is a fast and furious fray rather than an orchestrated chain of events, but the interplay between weak atomic forces and protein surface affinity are fundamental determinants of the ultimate cell colonization or lack thereof. Surface adsorption of proteins in quality and distribution is determined by physicochemical surface characteristics, and protein type, distribution, configuration, and ligand exposure determine opportunities for cell recognition depending on its binding strategy, whether it is a fast circulating platelet, a surface rolling monocyte, or a crawling endothelial cell. To control these material surface properties is to control blood and tissue interaction. This is not a trivial matter as surfaces are incredibly variegated from point to point, both chemically and topographically, when considered in the realm of nanometers rather than micrometers.
Where Do We Go From Here?
I certainly do not have a definitive answer; however, one thing is clear: There should be a radical change in mind-set. Innovation in cardiovascular devices in 2017 should be drastic and disruptive, committing to a departure from old methodology. This begins with looking outside of the traditional materials and manufacturing methods. The old paradigms of modulating the response to mechanical injury with antiproliferative drugs should be replaced by biofriendly and biomimetic approaches that are designed to promote healing through the restoration of tissue architecture. Furthermore, the concept of biological-prosthetic composites should be central to future developments. The idea of providing scaffolds for tissue to grow in an organized and functional manner should be extended to submicroscopic and perhaps nanoscopic levels. After all, this is the way we pointed, albeit in a crude way, with the early generation vascular stents 22 years ago. 23 Innovation in the area of large implantable devices such as the transluminal cardiac valve and the aortic stent-graft should begin by investigating new materials compatible with submicroscopic engineering, both on the blood-and tissue-contacting surfaces and in the material's bulk.
The differential vascular response between small and large vascular structures to implanted devices is related to the materials we use today. Excessive tissue proliferation in small arterial diameters and poor tissue healing response to large ones is at the center of the most important biological paradox we face with these devices. 24 Well-funded research programs in advanced bioprosthetics should be led by individuals or committees with knowledge of the goals and direction, striking a balance between realistic objectives and thinking "out of the box." The research team core should include cardiovascular physicians, molecular biologists, physical chemists, and materials experts. Neither one of these discipline representatives by themselves can attempt to succeed, as a well-balanced input of these essential components is needed. I have seen over the years well-intentioned and inspired research groups, almost invariably biased in one direction, chasing rabbit trails and misusing valuable time and resources. Research in areas like microfluidics, microscaffolds, and nanoassembly requires expensive equipment and infrastructure to maintain and keep them running at an efficient rate. A molecular biology and cytology laboratory working closely and in synchrony with the analytical materials and microfabrication teams is essential to maintain a dynamic flexibility in the progression of development.
The time for the lone cardiovascular device developer working in his or her garage is long gone. Trying to develop a new device with wire, solder, and pliers is not realistic today. The likelihood of one or multiple individuals making a significant contribution on limited resources and low-tech methods is by now close to zero. Young students wishing to invent a revolutionary device should choose an area of education and prepare to fit into a significant research system with big goals.
Just like when we gaze at the sky and dream of reaching far away worlds and galaxies, we should look into molecular and atomic interactions, water and ion behavior, and ligand-receptor relationships at the ultimate boundary: the material-host interface. There is a promise there, but to delve into this world we must step away from the rigid bounds we have imposed on our way of thinking: injury, inflammation, and modulation of tissue response with drugs.
Either the government or the industry or both should support novel and ambitious development programs. The medical community and the patients need to demand a change in the status quo and start by recognizing how stagnant progress in this area has been. Companies need to focus on long-term development and abandon the shortterm investment strategies leading to quick returns on investment for marginal improvements. An incentive should be established to reward ambitious goals. If the private aerospace industry is investing heavily in going to Mars, the medical industry should be inspired likewise. Arguably, improving the health of millions of aging patients burdened with cardiovascular disease is a loftier goal than space exploration. Fundamental programs of research in vascular prosthetics such as the artificial heart are struggling to maintain funding while electronic companies invest billions in research and development of gadgets we do not need until we are exposed to them.
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